Severe Mental Illness

On this page

Recognising Severe Mental Illness: Foundations and Epidemiology

Severe mental illness (SMI) encompasses conditions that profoundly disrupt cognition, perception, mood, and functioning, requiring sustained specialist intervention. The term typically includes schizophrenia, bipolar disorder, and severe treatment-resistant depression, though this lesson focuses primarily on the psychotic and mood spectrum disorders. A 28-year-old man presenting with persecutory delusions, auditory hallucinations, and social withdrawal exemplifies the diagnostic challenge: distinguishing first-episode psychosis requires careful exclusion of organic causes, substance-induced states, and affective psychosis. Understanding SMI epidemiology and classification is essential for early intervention, which significantly improves long-term outcomes.

Core Definitions and Classification:

  • Severe Mental Illness (SMI): Mental disorder causing substantial functional impairment in major life activities, typically requiring secondary care involvement for ≥2 years

    • Includes schizophrenia spectrum disorders, bipolar disorder, treatment-resistant depression with psychotic features
    • Distinguished from common mental disorders (anxiety, mild-moderate depression) by severity, chronicity, and service needs
  • Schizophrenia : Chronic psychotic disorder characterized by positive symptoms (hallucinations, delusions), negative symptoms (avolition, blunted affect), and cognitive impairment

    • Lifetime prevalence: 0.7-1.0% globally
    • Peak onset: males 18-25 years, females 25-35 years (bimodal distribution in women)
    • Median age of first presentation to services: 24 years
  • Bipolar Disorder : Episodic mood disorder with manic/hypomanic episodes, often alternating with depressive episodes

    • Lifetime prevalence: 1-2% (Bipolar I ~0.6%, Bipolar II ~0.4%)
    • Mean age of onset: 21 years (earlier than unipolar depression)
    • 10-15% of individuals with recurrent depression will develop bipolar disorder
ConditionPrevalencePeak Onset (years)Male:Female RatioPsychotic Features
Schizophrenia0.7-1.0%18-35 (bimodal)1.4:1Core feature (100%)
Bipolar I0.6%15-251:150-70% during mania
Bipolar II0.4%20-301:1.5 (F>M)Rare (5-10%)

📌 Mnemonic for SMI Core Features: SPICE - Severity (functional impairment), Persistence (chronicity), Impairment (occupational/social), Complexity (multidomain), Engagement (specialist services required)

Epidemiological Risk Factors:

  • Schizophrenia risk factors:

    • Family history: 10-fold increased risk with first-degree relative
    • Cannabis use: 2-4× risk, dose-dependent, especially high-potency strains
    • Urban birth/upbringing: 2× risk compared to rural settings
    • Migration status: 2-3× risk in first/second-generation migrants
    • Advanced paternal age (>35 years): 1.3× risk per decade
  • Bipolar disorder risk factors:

    • Family history: 10× risk with affected first-degree relative (strongest genetic component in psychiatry)
    • Childhood adversity: 2-3× risk with trauma/abuse
    • Sleep disruption: precipitates manic episodes in vulnerable individuals

Figure 1: MRI brain scan showing reduced grey matter volume in bilateral temporal lobes and enlarged lateral ventricles in chronic schizophrenia

Recognising Severe Mental Illness: Foundations and Epidemiology

2 - Neurobiology and Symptom Formation: Understanding the Mechanisms

The neurobiological substrate of severe mental illness involves dysregulation across multiple neurotransmitter systems, particularly dopamine, glutamate, and serotonin pathways. In schizophrenia , the dopamine hypothesis posits mesolimbic hyperactivity (producing positive symptoms) alongside mesocortical hypoactivity (contributing to negative symptoms and cognitive deficits). Bipolar disorder involves dysregulation of monoaminergic systems, circadian rhythm disruption, and altered neuroplasticity. These mechanisms explain symptom clusters, guide pharmacological targeting, and clarify why treatment responses differ across symptom domains.

Schizophrenia Neurobiology:

  • Dopamine pathways:

    • Mesolimbic hyperactivity: Excessive D2 receptor stimulation in nucleus accumbens → positive symptoms (hallucinations, delusions)
    • Mesocortical hypoactivity: Reduced dopamine in prefrontal cortex → negative symptoms, executive dysfunction
    • Nigrostriatal pathway: Antipsychotic D2 blockade here causes extrapyramidal side effects (EPSE)
    • Tuberoinfundibular pathway: D2 blockade → hyperprolactinemia
  • NMDA receptor hypofunction: Glutamate deficiency model explains cognitive impairment and negative symptoms

    • Phencyclidine (PCP) and ketamine (NMDA antagonists) reproduce schizophrenia-like symptoms
    • Rationale for glutamatergic augmentation strategies (e.g., glycine, D-serine)
  • Structural changes:

    • Ventricular enlargement (10-15% volume increase)
    • Reduced hippocampal and prefrontal grey matter
    • Progressive changes suggest neurodevelopmental + neurodegenerative components

Bipolar Disorder Neurobiology:

  • Monoamine dysregulation:

    • Mania: Excess dopamine and noradrenaline activity
    • Depression: Deficiency in serotonin, noradrenaline, dopamine
    • Explains therapeutic efficacy of mood stabilizers (lithium, valproate) that modulate multiple systems
  • Circadian rhythm disruption:

    • Sleep deprivation precipitates mania in 25-30% of vulnerable individuals
    • Melatonin and cortisol dysregulation documented
    • Rationale for sleep hygiene and circadian-focused interventions

Symptom Cluster Architecture:

DomainSchizophrenia ExamplesBipolar Mania ExamplesNeurobiological Basis
PositiveAuditory hallucinations, persecutory delusionsGrandiose delusions, mood-congruent hallucinationsMesolimbic dopamine excess
NegativeAvolition, alogia, anhedonia(Not applicable)Mesocortical dopamine deficit
CognitiveWorking memory, executive function deficitsDistractibility, poor judgmentPrefrontal cortex dysfunction
MoodDepression (25% comorbid), blunted affectEuphoria, irritability, labilityMonoamine dysregulation

2 — Neurobiology and Symptom Formation: Understanding the Mechanisms

3 - Diagnostic Formulation: Applying ICD-11 and DSM-5 Criteria

A 32-year-old woman presents with three weeks of reduced sleep (3 hours/night), pressured speech, excessive spending (£15,000 on credit cards), and grandiose beliefs about starting a tech company despite no relevant experience. She has no psychiatric history but her mother has bipolar disorder. Distinguishing manic episode from substance-induced mania, schizophrenia with affective symptoms, or personality-driven impulsivity requires systematic application of diagnostic criteria. NICE CG178 (psychosis and schizophrenia) and NICE CG185 (bipolar disorder) emphasize early recognition, comprehensive assessment, and prompt initiation of evidence-based treatment.

Schizophrenia Diagnostic Criteria (ICD-11):

  • Minimum duration: Symptoms present for ≥1 month

  • Core symptoms (≥2 required):

    • Persistent delusions (bizarre or non-bizarre)
    • Persistent hallucinations (any modality, typically auditory)
    • Disorganized thinking (formal thought disorder)
    • Disorganized behavior or catatonia
    • Negative symptoms (diminished emotional expression, avolition)
  • Exclusion criteria:

    • Substance/medication-induced (check urine toxicology)
    • Organic cause (neuroimaging, metabolic screen, autoimmune encephalitis panel)
    • Mood disorder with psychotic features (temporal relationship crucial)

Bipolar Disorder Diagnostic Criteria (DSM-5):

  • Manic Episode (Bipolar I):

    • Abnormally elevated/expansive/irritable mood ≥7 days (or any duration if hospitalization required)
    • ≥3 symptoms (4 if mood only irritable): DIGFAST mnemonic
    • Marked functional impairment or psychotic features present
  • Hypomanic Episode (Bipolar II):

    • Similar symptoms but ≥4 days duration
    • Observable change in functioning but no marked impairment
    • No psychotic features (presence indicates Bipolar I)

📌 Mnemonic for Mania: DIGFAST - Distractibility, Indiscretion (excessive involvement in pleasurable activities), Grandiosity, Flight of ideas, Activity increase, Sleep deficit (decreased need), Talkativeness (pressured speech)

Essential Investigations:

  • Baseline screening (all first-episode psychosis/mania):

    • FBC, U&E, LFTs, TFTs, glucose, calcium, HbA1c
    • Urine toxicology (cannabis, amphetamines, cocaine)
    • Syphilis serology, HIV test (if risk factors)
    • MRI brain (exclude structural lesions, demyelination)
    • ECG (baseline before antipsychotics, especially QTc interval)
  • Extended screen if atypical features:

    • Autoimmune encephalitis panel (anti-NMDA receptor antibodies)
    • Serum ceruloplasmin and 24h urinary copper (Wilson's disease if <40 years)
    • EEG (if seizures, confusion, or rapid cognitive decline)

Figure 2: PET scan showing increased dopamine synthesis capacity in striatum of patient with schizophrenia compared to healthy control

3 — Diagnostic Formulation: Applying ICD-11 and DSM-5 Criteria

4 - Differential Diagnosis: Analyzing Diagnostic Challenges

Distinguishing schizophrenia from schizoaffective disorder, bipolar disorder with psychotic features, and substance-induced psychosis represents a common clinical challenge. Temporal relationships between mood and psychotic symptoms are critical: in schizoaffective disorder, psychosis persists for ≥2 weeks in the absence of mood symptoms, whereas in bipolar disorder with psychotic features, psychosis occurs only during mood episodes. Diagnostic stability is poor in early illness-up to 25% of first-episode psychosis diagnoses change over 3 years as longitudinal patterns emerge.

Key Diagnostic Discriminators:

FeatureSchizophreniaBipolar I with PsychosisSchizoaffective Disorder
Mood episodesAbsent or brief relative to psychosisProminent, define episodesProminent but psychosis persists independently ≥2 weeks
Psychotic symptoms outside mood episodesPresent (core feature)AbsentPresent (≥2 weeks without mood symptoms)
Negative symptomsProminent, persistentAbsent or only during depressionVariable
Functional trajectoryProgressive decline commonEpisodic with inter-episode recoveryIntermediate between schizophrenia and bipolar
Family historySchizophrenia > bipolarBipolar > schizophreniaBoth conditions increased

Substance-Induced Psychosis:

  • Cannabis-induced psychosis:

    • Typically resolves within 1 month of abstinence (if persistent beyond this, consider primary psychotic disorder)
    • High-potency cannabis (>10% THC): 4-5× risk of persistent psychosis
    • 25-30% of cannabis-induced psychosis transitions to schizophrenia within 3 years
  • Stimulant-induced psychosis (amphetamines, cocaine):

    • Paranoid delusions predominate; visual hallucinations more common than in schizophrenia
    • Usually resolves within 7-10 days of cessation
    • Positive urine toxicology confirms recent use but doesn't exclude comorbid primary disorder

Organic Psychosis Red Flags:

  • Age of onset <15 or >40 years (atypical for primary psychotic disorders)
  • Acute confusion or fluctuating consciousness (suggests delirium)
  • Visual hallucinations predominating over auditory (suggests organic cause)
  • Focal neurological signs, seizures, or movement disorder
  • Rapid cognitive decline or memory impairment

🚩 Red Flag: New-onset psychosis in patient >40 years requires urgent neuroimaging and comprehensive organic screen-likelihood of structural/metabolic cause approaches 20-25% in this age group.

4 — Differential Diagnosis: Analyzing Diagnostic Challenges

5 - Evidence-Based Management: Evaluating Treatment Strategies

NICE CG178 recommends offering oral antipsychotic medication to all individuals with first-episode psychosis, combined with family intervention and individual CBT for psychosis. Treatment goals differ between schizophrenia -focused on symptom reduction and relapse prevention-and bipolar disorder -emphasizing mood stabilization and preventing episode recurrence. The choice between typical and atypical antipsychotics balances efficacy against side-effect profiles, with monitoring requirements varying by agent.

Schizophrenia Pharmacological Management:

  • First-line antipsychotics (NICE CG178):

    • Offer oral atypical antipsychotic (risperidone, olanzapine, quetiapine, aripiprazole, amisulpride)
    • Start at low dose, titrate to minimum effective dose over 1-2 weeks
    • Avoid polypharmacy in first episode
  • Specific dosing examples:

    • Risperidone: Start 2mg daily, target 4-6mg daily (max 16mg)
    • Olanzapine: Start 5-10mg daily, target 10-20mg daily
    • Aripiprazole: Start 10-15mg daily, target 10-30mg daily
    • Response expected within 2-4 weeks for positive symptoms; negative symptoms respond more slowly
  • Treatment-resistant schizophrenia:

    • Defined as inadequate response to ≥2 antipsychotics (including one atypical) at adequate dose for 6-8 weeks each
    • Clozapine: Only licensed treatment for treatment-resistant schizophrenia
    • Start 12.5mg daily, titrate gradually to 300-450mg daily (max 900mg)
    • Requires weekly FBC for 18 weeks (neutropenia risk 0.8%), then fortnightly to 1 year, then monthly

Bipolar Disorder Acute and Maintenance Treatment:

  • Acute mania (NICE CG185):

    • First-line: Antipsychotic (haloperidol, olanzapine, quetiapine, risperidone) OR valproate
    • Valproate: Load 20-30mg/kg daily in divided doses, target plasma level 50-125mg/L
    • Olanzapine: 15-20mg daily in acute mania (higher than schizophrenia dosing)
    • If inadequate response within 3-7 days, consider combination therapy or switch
  • Maintenance treatment:

    • Lithium: First-line mood stabilizer; start 400mg daily, titrate to plasma level 0.6-1.0 mmol/L
    • Check lithium level weekly until stable, then 3-monthly long-term
    • Monitor U&E, TFTs, calcium 6-monthly (nephrotoxicity and hypothyroidism risks)
    • Valproate: 500-1000mg daily, avoid in women of childbearing potential (teratogenicity)
AntipsychoticStarting DoseTarget DoseKey MonitoringNotable Side Effects
Risperidone2mg daily4-6mg dailyProlactin, EPSEHyperprolactinemia (60%), EPSE
Olanzapine5-10mg daily10-20mg dailyWeight, glucose, lipidsWeight gain (+5kg in 40%), metabolic syndrome
Aripiprazole10-15mg daily10-30mg dailyAkathisiaAkathisia (25%), activation
Clozapine12.5mg daily300-450mg dailyFBC weekly→monthly, ECGNeutropenia (0.8%), myocarditis (rare), hypersalivation

5 — Evidence-Based Management: Evaluating Treatment Strategies

6 - Complex Cases and Special Populations: Synthesizing Advanced Approaches

Real-world management requires integrating pharmacotherapy with psychosocial interventions, addressing comorbidities, and adapting treatment for special populations. Approximately 50% of individuals with schizophrenia have comorbid substance use disorder, and 40-60% of those with bipolar disorder experience anxiety disorders. Pregnancy, elderly patients, and treatment-resistant cases demand modified approaches balancing efficacy against safety. Recovery-oriented care emphasizes functional outcomes beyond symptom reduction, with early intervention services demonstrating 20-30% reduction in relapse rates compared to standard care.

Pregnancy and Perinatal Management:

  • Schizophrenia in pregnancy:

    • Continue antipsychotic if clinically stable (relapse risk 50-60% if discontinued)
    • Olanzapine or quetiapine preferred (most safety data)
    • Avoid depot preparations (inability to rapidly discontinue if needed)
    • Neonatal monitoring for EPSE and sedation (transient, resolves within days)
  • Bipolar disorder in pregnancy:

    • Avoid valproate (neural tube defects 10%, neurodevelopmental delay)
    • Lithium: Relative contraindication (Ebstein anomaly risk 0.05-0.1% vs 0.005% baseline)
    • If lithium continued, check levels monthly (clearance increases 30-50% in pregnancy)
    • Postpartum period: highest risk for relapse (40-50% within 3 months)-reinitiate prophylaxis immediately after delivery

Elderly Patients:

  • Increased sensitivity to antipsychotics: start at 50% standard dose
  • EPSE risk 2-3× higher; avoid high-potency typicals (haloperidol)
  • Stroke risk warning (atypicals in dementia): 1.5-2× increased risk, but applies to dementia-related psychosis, not primary SMI
  • Lithium clearance reduced: target lower levels (0.4-0.6 mmol/L), check renal function 3-monthly

Treatment-Resistant and Complex Cases:

  • Clozapine augmentation strategies (after adequate clozapine trial to 900mg):

    • Amisulpride augmentation (200-400mg daily)
    • ECT for catatonia or treatment-resistant schizophrenia with affective symptoms
    • CBT for psychosis (reduces distress and improves functioning even when symptoms persist)
  • Rapid cycling bipolar disorder (≥4 episodes/year):

    • Occurs in 10-20% of bipolar patients
    • Lithium + valproate combination more effective than monotherapy
    • Address thyroid dysfunction (even subclinical hypothyroidism worsens cycling)

Clinical Pearl: In treatment-resistant cases, verify adherence (plasma drug levels), optimize dose, ensure adequate trial duration (6-8 weeks), and exclude substance use before labeling as treatment-resistant. Up to 40% of apparent resistance reflects non-adherence or inadequate dosing.

6 — Complex Cases and Special Populations: Synthesizing Advanced Approaches

High Yield Summary

Key Take-Aways:

  • Schizophrenia affects 0.7-1.0% of population with peak onset 18-35 years; bipolar disorder affects 1-2% with onset typically 15-30 years
  • Diagnostic criteria require ≥1 month symptoms for schizophrenia; ≥7 days elevated mood for mania (≥4 days for hypomania)
  • First-line treatment: oral atypical antipsychotics for schizophrenia; antipsychotic or valproate for acute mania; lithium for bipolar maintenance
  • Treatment resistance defined as failure of ≥2 antipsychotics at adequate dose for 6-8 weeks; clozapine is only licensed treatment
  • Lithium requires plasma level 0.6-1.0 mmol/L, checked weekly until stable then 3-monthly, with 6-monthly U&E/TFT monitoring
  • Cannabis-induced psychosis persisting >1 month after abstinence suggests transition to primary psychotic disorder (25-30% risk)
  • Pregnancy: continue antipsychotics if needed (olanzapine/quetiapine preferred); avoid valproate (10% neural tube defect risk)

Essential Severe Mental Illness Numbers:

ParameterValueClinical Significance
Schizophrenia lifetime prevalence0.7-1.0%~1 in 100 population
Bipolar disorder lifetime prevalence1-2%Bipolar I 0.6%, Bipolar II 0.4%
First-degree relative risk (schizophrenia)10× baselineStrongest risk factor
Cannabis-induced psychosis transition rate25-30%High conversion to primary disorder
Treatment-resistant schizophrenia30% of casesRequires clozapine consideration
Lithium therapeutic range0.6-1.0 mmol/LNarrow therapeutic window
Clozapine neutropenia risk0.8%Mandates weekly FBC initially
Relapse rate if antipsychotic stopped50-60% within 6 monthsJustifies maintenance treatment

Key Principles/Pearls:

  • Temporal relationships between mood and psychotic symptoms distinguish bipolar disorder with psychosis (psychosis only during mood episodes) from schizoaffective disorder (psychosis persists ≥2 weeks independently)
  • Always exclude organic causes in first-episode psychosis: neuroimaging, metabolic screen, toxicology-especially if age >40 years or atypical features present
  • Negative symptoms and cognitive deficits cause more long-term disability than positive symptoms in schizophrenia but respond poorly to current antipsychotics
  • Early intervention within 3 months of psychosis onset improves outcomes; duration of untreated psychosis predicts treatment response
  • Avoid valproate in women of childbearing potential-teratogenicity risk mandates pregnancy prevention program if no alternative

Quick Reference:

Clinical ScenarioActionKey Numbers
First-episode psychosisOral atypical antipsychotic + CBT + family interventionResponse expected 2-4 weeks
Acute maniaAntipsychotic (olanzapine 15-20mg) or valproate (load 20-30mg/kg)Reassess at 3-7 days
Treatment-resistant schizophreniaClozapine 12.5mg→300-450mg, weekly FBC×18 weeksAfter 2 failed trials (6-8 weeks each)
Bipolar maintenanceLithium 400mg→target level 0.6-1.0 mmol/LCheck level weekly→3-monthly
Suspected substance-induced psychosisUrine toxicology, observe 1 month abstinenceIf persists >1 month, likely primary disorder

Practice Questions: Severe Mental Illness

Test your understanding with these related questions

A 30-year-old woman presents with episodes of feeling detached from herself and her surroundings, as if watching herself from outside her body. These episodes last 10-15 minutes and cause significant distress. What is the most likely diagnosis?

1 of 5

Flashcards: Severe Mental Illness

1/9

Dopamine agonists (e.g. pramipexole, ropinirole) may _____ impulsive activities such as gambling, hypersexuality, shopping, & binge eating

Hint: ↓/↑

TAP TO REVEAL ANSWER

Dopamine agonists (e.g. pramipexole, ropinirole) may _____ impulsive activities such as gambling, hypersexuality, shopping, & binge eating

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial